Bicara Therapeutics (NASDAQ:BCAX) CEO Ryan Cohlhepp Sells 17,500 Shares

Bicara Therapeutics Inc. (NASDAQ:BCAX) CEO Ryan Cohlhepp sold 17,500 shares of the company’s stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $22.90, for a total value of $400,750.00. Following the completion of the sale, the chief executive officer directly owned 181,641 shares in the company, valued at approximately $4,159,578.90. The trade was a 8.79% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ryan Cohlhepp also recently made the following trade(s):

• On Monday, August 10th, Ryan Cohlhepp sold 18,750 shares of Bicara Therapeutics stock. The shares were sold at an average price of $27.98, for a total value of $524,625.00.
• On Thursday, July 9th, Ryan Cohlhepp sold 536 shares of Bicara Therapeutics stock. The stock was sold at an average price of $29.00, for a total value of $15,544.00.
• On Wednesday, July 8th, Ryan Cohlhepp sold 28,214 shares of Bicara Therapeutics stock. The stock was sold at an average price of $28.98, for a total value of $817,641.72.

Bicara Therapeutics Stock Down 2.3%

NASDAQ BCAX opened at $23.10 on Friday. Bicara Therapeutics Inc. has a fifty-two week low of $10.30 and a fifty-two week high of $30.99. The business has a fifty day moving average of $26.01 and a 200-day moving average of $22.98. The stock has a market cap of $1.53 billion, a price-to-earnings ratio of -7.45 and a beta of -0.82.

Bicara Therapeutics (NASDAQ:BCAX) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.82) EPS for the quarter, hitting analysts’ consensus estimates of ($0.82). As a group, analysts anticipate that Bicara Therapeutics Inc. will post -3.51 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on BCAX shares. Wall Street Zen raised shares of Bicara Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, May 24th. The Goldman Sachs Group raised their target price on shares of Bicara Therapeutics from $18.00 to $20.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 12th. Wedbush lifted their target price on shares of Bicara Therapeutics from $30.00 to $33.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 12th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Bicara Therapeutics in a report on Thursday. Finally, Morgan Stanley increased their price target on Bicara Therapeutics from $37.00 to $39.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 11th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Bicara Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $32.64.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. AQR Capital Management LLC acquired a new stake in shares of Bicara Therapeutics in the first quarter worth approximately $248,000. Woodline Partners LP increased its position in Bicara Therapeutics by 26.5% during the first quarter. Woodline Partners LP now owns 348,690 shares of the company’s stock worth $4,543,000 after purchasing an additional 72,998 shares during the last quarter. Geode Capital Management LLC increased its position in Bicara Therapeutics by 36.8% during the second quarter. Geode Capital Management LLC now owns 672,485 shares of the company’s stock worth $6,248,000 after purchasing an additional 180,833 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Bicara Therapeutics by 26.0% during the second quarter. JPMorgan Chase & Co. now owns 27,458 shares of the company’s stock worth $255,000 after purchasing an additional 5,664 shares during the period. Finally, Legal & General Group Plc raised its stake in Bicara Therapeutics by 64.1% during the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after purchasing an additional 1,233 shares during the period.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.